Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Pegaptanib Combined With Intravitreal Injection of Moxifloxacin as Treatment of Wet Macular Degeneration

Bennett, Michael D. MD; Yee, Wendy MD; Bryan, J Shepard MD

doi: 10.1097/IAE.0b013e3181733733
Original Articles

Purpose: To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.

Methods: This retrospective review included patients who received pegaptanib combined with 165 μg of moxifloxacin every 6 weeks. Ophthalmic examination was performed, and adverse events were recorded at each visit; additional assessments (e.g., optical coherence tomography) were performed when indicated.

Results: Eighty eyes of 65 patients were identified; the median length of follow-up was 13.2 months (range, 10–16 months), and eyes received an average of 6 injections (range, 4–9 months). Seventy eyes of 80 patients have been followed for ≥1 year; 80% (65/70) had stable or improved vision, and 97% (68/70) lost <15 letters of vision.

Conclusion: Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.

Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.

From the Retina Institute of Hawaii, Honolulu, Hawaii.

The authors have no proprietary interest related to this article.

Reprint requests: Michael D. Bennett, MD, Retina Institute of Hawaii, 1620 Ala Moana Boulevard #500, Honolulu, HI 96815; e-mail: mbennett@retinahawaii.com

© The Ophthalmic Communications Society, Inc.